Cerebrovascular disease (CVD) is the third
most common cause of death worldwide. CVD accounts for the major cause of
morbidity and mortality in industrialized countries and responsible for stroke
and transient ischemic attack (TIA).
There are about 500,000 new or recurrences
stroke cases each year. Simvastatin (epistatin), an HMG-CoA reductase
inhibitor, acts by decreasing cholesterol synthesis and by increasing low
density lipoprotein (LDL) catabolism via increased LDL receptor activity.
Simvastatin was beneficial in a lot of immunologic VCD. Evidences indicated
that simvastatin could stable plaque and improve the long-term prognosis of
patients with CVD. Read More>>>>>>>>
No comments:
Post a Comment